Research/Paper

PubMedReview

Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation.

Khavinson Vladimir, Linkova Natalia, Dyatlova Anastasiia, Kantemirova Raisa, Kozlov Kirill

Cells2022DOI: 10.3390/cells12010106

liraglutideatrial natriuretic peptiderelaxin mimeticsUcn1adropinKED tripeptideAEDR tetrapeptide

Quality Score

7/10

Citations

Subjects

Non-Human

Peptide Contacts Analysis

Study Design

Review papers serve a critical role in synthesizing disparate findings into a coherent narrative. For rapidly evolving fields like peptide therapeutics, reviews help researchers and practitioners identify consensus and controversy.

Our Assessment

Quality Assessment: 7/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

These findings advance our understanding of liraglutide, atrial natriuretic peptide, relaxin mimetics, Ucn1, adropin, KED tripeptide, AEDR tetrapeptide in meaningful ways.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Strong methodology makes this a valuable addition to the liraglutide, atrial natriuretic peptide, relaxin mimetics, Ucn1, adropin, KED tripeptide, AEDR tetrapeptide evidence base. The findings here should inform future clinical trial design.

Key Findings

The review highlights the role of senescence-associated secretory phenotype (SASP) and inflammaging in cardiovascular diseases, identifying peptides as potential regulators of SASP-related molecules. It suggests that vasoprotective polypeptides could be developed into drugs for treating age-related cardiovascular conditions.

Limitations

As a review paper, it does not present new experimental data but synthesizes existing literature, which may limit its ability to provide definitive conclusions about the efficacy and safety of peptides in clinical settings.

How to Interpret This Research

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

Reviews are only as good as the studies they include. Check whether the review examined study quality or simply tallied results.

Look for discussion of publication bias — studies with negative results are less likely to be published, which can skew review conclusions.

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Peptide Contacts Analysis

Highlighting the role of peptides in regulating senescence-associated secretory phenotype (SASP) and inflammaging, with a focus on their potential as therapeutic agents for age-related cardiovascular diseases.

liraglutideatrial natriuretic peptiderelaxin mimeticsUcn1adropinKED tripeptideAEDR tetrapeptide

Harnessing Peptides to Combat Age-Related Cardiovascular Diseases

Published: May 17, 2026 | Source: Cells (2022) | Category: liraglutide, atrial natriuretic peptide, relaxin mimetics, Ucn1, adropin, KED tripeptide, AEDR tetrapeptide

Overview

A recent review in the journal Cells highlights how peptides can play a crucial role in regulating senescence-associated secretory phenotype (SASP) and inflammaging, which are key contributors to age-related cardiovascular diseases. This research underscores the potential of specific vasoprotective polypeptides as therapeutic agents for managing conditions like atherosclerosis and myocardial infarction.

Study Background

As people age, cells in the body undergo senescence—a state where they stop dividing but remain metabolically active, often releasing inflammatory molecules that contribute to chronic inflammation (inflammaging). This process is linked to various cardiovascular diseases. Researchers have long sought ways to mitigate these effects and improve heart health in older individuals. The review synthesizes existing literature on peptides' role in regulating SASP-related molecules in the cardiovascular system.

What the Research Found

The study found that senescent cells of the cardiovascular system exhibit altered synthesis of proteins such as p16, p21, and p53, which are known to inhibit cell proliferation. Additionally, these cells produce cytokines like IL-1α, IL-6, TNFα, and TGFβ1, all of which contribute to inflammaging. The review also identified several peptides that can regulate the synthesis of molecules involved in SASP and inflammaging, including liraglutide, atrial natriuretic peptide (ANP), relaxin mimetics, Ucn1, adropin, KED tripeptide, and AEDR tetrapeptide. These peptides have shown promise in modulating the inflammatory response and potentially reversing some aspects of cellular senescence.

What This Means for Peptide Users

For those using or considering peptide therapy, this research suggests that certain vasoprotective polypeptides might offer a new avenue to manage age-related cardiovascular conditions. However, it is important to note that while these peptides show potential in laboratory settings and animal models, their efficacy and safety in human clinical trials remain to be fully established.

Limitations and Caveats

As a review paper, the study does not present any new experimental data but rather synthesizes existing literature. This means that definitive conclusions about the therapeutic value of peptides cannot yet be drawn based on this work alone. Additionally, while promising results have been observed in preclinical studies, more research is needed to understand how these peptides might function in human patients and what potential side effects they may carry.

How This Compares to Previous Research

This review aligns with previous findings that highlight the importance of SASP and inflammaging in cardiovascular health. However, it uniquely emphasizes the role of peptides as potential regulators of these processes. Other studies have focused on different therapeutic approaches or broader mechanisms without specifically targeting peptide-based interventions for cardiovascular diseases.

Our Analysis

PeptideVault views this review positively, recognizing its contribution to understanding how specific peptides might influence SASP and inflammaging in cardiovascular cells. However, we also acknowledge the need for more rigorous clinical trials to validate these findings before recommending any changes in treatment protocols. The research provides a solid foundation for future studies but falls short of providing conclusive evidence for immediate therapeutic application.

Key Takeaways

Peptides show promise as regulators of SASP and inflammaging in cardiovascular cells.
Specific vasoprotective polypeptides like liraglutide, ANP, relaxin mimetics, Ucn1, adropin, KED tripeptide, and AEDR tetrapeptide are highlighted for their potential therapeutic benefits.
Further clinical research is necessary to confirm the safety and efficacy of these peptides in human patients.

Original Source

Citation: Khavinson Vladimir, Linkova Natalia, Dyatlova Anastasiia et al. (2022). Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation.. Cells. DOI: 10.3390/cells12010106

Access: https://pubmed.ncbi.nlm.nih.gov/36611900/

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was written by the Peptide Contacts research team to make complex findings accessible to the peptide community. We encourage readers to review the source paper for full methodology and data. For more on liraglutide, explore our research guides.

Citation

Khavinson Vladimir, Linkova Natalia, Dyatlova Anastasiia et al.. (2022). Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation.. Cells. https://doi.org/10.3390/cells12010106

View full text on PubMed

Related Papers

Medications for Obesity: A Review.

Gudzune Kimberly A et al.· JAMA· 2024Meta-Analysis

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.

Rubino Domenica M et al.· JAMA· 2022Randomized Controlled Trial

Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.

Silver Heidi J et al.· Diabetes, obesity & metabolism· 2023Randomized Controlled Trial

A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.

Min Jee Sun et al.· Drug design, development and therapy· 2025Review

Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.

Thomsen Reimar W et al.· Diabetes, obesity & metabolism· 2025Review

Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.

Liu Lulu et al.· Frontiers in endocrinology· 2022Review

Explore Further

Research Library

Browse all indexed papers

Research Guides

Plain-language peptide guides

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.